TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

The RNA Oncology Company​™

Rapidly Advancing New Scientific Discoveries to Transform the Way Cancer is Treated

Using its proprietary delivery system, TransCode Therapeutics is developing targeted RNA therapeutics designed to target tumor cells and with its initial focus, tackle one of the most feared stages of cancer -- cancer progression or metastasis. ​
TransCode Therapeutics believes it has overcome the greatest barrier to harnessing RNA technology for cancer treatment — the targeting of RNA therapeutics to cancer cells

Learn How
TransCode's lead therapeutic candidate TTX-MC138 has the potential to treat a variety of tumor indications that are known to become metastatic.
Explore Pipeline

Power and Potential of RNA-based Therapies

The power of RNA therapeutics lies in their ability to target any gene which enables rational and straightforward drug design. RNA-based therapeutics are highly selective to their targets, potentially making available a broad array of previously undruggable targets in cancer including metastasis.
Read More
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers